Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncoceutics secures grant for phase II brain cancer trial
The company previously received the first part of the award in March 2015 and successfully completed part one. Part two of the Fast-Track SBIR award totals $1.4 million
The company previously received the first part of the award in March 2015 and successfully completed part one. Part two of the Fast-Track SBIR award totals $1.4 million
UL EduNeering, a leading provider of quality and compliance training solutions for regulated industries, will educate all CDSCO inspectors and regulators with the UL e-learning modules, co-developed and
The company expects to report preliminary top-line data by the end of the fourth quarter of 2015. PINTA 745 is a peptibody that binds myostatin and inhibits its
French pharmaceutical firm Sanofi will work with Google’s life sciences team to collect, analyze and understand information impacting diabetes. According to the International Diabetes Federation, diabetes is anticipated
The agreement formalizes a relationship between QB3@953 and GSK’s Discovery Partnerships with Academia (DPAc) team and creates a new channel for DPAc to identify early-stage opportunities. The agreement
The Israeli patent application No. 207420 is entitled "Methods and Compositions for Treating Inflammatory Bowel Disease". Once granted, the patent is expected to be valid through at least
Cobimetinib is a selective inhibitor of MEK that was discovered by Exelixis and is the subject of a worldwide collaboration agreement between Exelixis and Genentech, a member of
The programme aims to support research into areas of medical need in cardiovascular medicine. Four grants of up to €400,000 each will be awarded to researchers or clinicians
STA is now the only Chinese contract manufacturing organization to have received approval to supply active pharmaceutical ingredients (APIs) and GMP intermediates for branded commercial drugs from regulatory
Earlier this year Symbiomix announced positive results from the first pivotal trial for SYM-1219. Symbiomix expects to finish this second pivotal trial by the end of 2015, which